WIRE — HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in... The post Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis appeared first on Kosmo Digital.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.